Isis Innovation: How the Oxford Sciences Innovation fund is promoting investment in the Oxfordshire region




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Isis Innovation: How the Oxford Sciences Innovation fund is promoting investment in the Oxfordshire region
Released on: March 03, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Adam Stoten, head of Technology Transfer at Isis Innovation (the technology transfer arm of the University of Oxford) discusses the recent successes of Oxford Sciences Innovation (OSI), a fund comprising six key investors: Invesco Asset Management Limited, IP Group plc, Lansdowne Partners (UK) LLP, Oxford University Endowment Fund, the Wellcome Trust, and Woodford Investment Management LLP.
  • Summary
  • Transcript
  • Participants
  • Company
Adam Stoten, head of Technology Transfer at Isis Innovation (the technology transfer arm of the University of Oxford) discusses the recent successes of Oxford Sciences Innovation (OSI), a fund comprising six key investors: Invesco Asset Management Limited, IP Group plc, Lansdowne Partners (UK) LLP, Oxford University Endowment Fund, the Wellcome Trust, and Woodford Investment Management LLP.
Adam Stoten, head of Technology Transfer at Isis Innovation (the technology transfer arm of the University of Oxford) discusses the recent successes of Oxford Sciences Innovation (OSI), a fund comprising six key investors: Invesco Asset Management Limited, IP Group plc, Lansdowne Partners (UK) LLP, Oxford University Endowment Fund, the Wellcome Trust, and Woodford Investment Management LLP.
Adam joined Isis in the role of Deputy Head of Technology Transfer in 2013, with specific responsibility for commercialisation of life/medical science technologies originating from Oxford research, and for managing Isis’ partnership with OUHT. Adam has more than a decade’s experience in the pharma/biotech sector in commercial roles encompassing business development and licensing, new venture formation, product development, lobbying/advocacy and general management. Between 2010 and 2013 Adam worked as Deputy General Manager for the Oxford-Emergent Tuberculosis Consortium Ltd, a joint venture between the University of Oxford and Emergent BioSolutions Inc, which conducted the first ever efficacy study of a new TB vaccine in infants. Adam first worked at Isis between 2005 and 2010 as a Project Manager and subsequently a Team Leader in the Technology Transfer Group, successfully managing a wide range of licensing deals and spin-outs spanning therapeutics, vaccines, diagnostics, research tools and software. Prior to 2005 he worked for a biotechnology consultancy undertaking due diligence and market research projects. Adam has a 1st Class Honours degree in biology and a PhD in immunology from the University of Nottingham.
The Technology Transfer group works with University researchers who want to commercialise their IP through licensing, spin-out formation and material sales. The group also incorporates Isis Outcomes, which provides access to high quality Patient Reported Outcome (PRO) measures developed at the University of Oxford and other institutions, and the Isis Startup Incubator, which allows Oxford-related entrepreneurs to develop software IP based on copyright and know-how only. The Isis Angels Network provides information and networking events for investors seeking updates on new opportunities..